TMCI - Agiliti gains two buy recommendations Magenta initiated as a buy and more in analyst action

Recent IPO Agiliti named a buy at KeyBanc, BMOMedical equipment management firm Agiliti (AGTI), which started trading next month, has earned an overweight rating at KeyBanc and an outperform rating at BMO.KeyBanc has a $21 price target (~43% upside), while BMO's target is $18 (~22% upside).KeyBanc's Matthew Mishan says the company has an unparalleled national footprint and is very profitable.He adds that the current valuation doesn't reflect long-term growth potential.BMO analyst Matt Borsch says that investors have incorrectly priced Agiliti as a "hospital stock" implying slower growth and higher reimbursement risk.Magenta a buy on stem cell transplant potentialMagenta's (MGTA) lead candidates in the stem cell transplant space could reap dividends for the company, making it a buy, according to B. Riley.Analyst Kalpit Patel has a $21 price target (90% upside) on shares.Patel writes that the company's most advanced candidates "could transform the standard prerequisite protocols for stem cell transplants."He adds that

For further details see:

Agiliti gains two buy recommendations, Magenta initiated as a buy and more in analyst action